Skip to content

ClearPoint Neuro CLPT Accounts Receivable, Credit Loss Expense (Reversal)

Accounts Receivable, Credit Loss Expense (Reversal) at other companies

Medtronic logo
MedtronicMDT
AngioDynamics logo
AngioDynamicsANGO
Globus Medical logo
Globus MedicalGMED
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
Net income-$9.6M-58.5%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%
Free cash flow-$8.6M-35.5%

Valuation

See full
Market cap$538.61M+69.2%
Enterprise value$565.68M+82.9%
P/S13.3×+3.4×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's accounts receivable, credit loss expense (reversal).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ClearPoint Neuro's accounts receivable, credit loss expense (reversal)?
ClearPoint Neuro (CLPT) reported accounts receivable, credit loss expense (reversal) of -$95K in Q1 2026.
How has ClearPoint Neuro's accounts receivable, credit loss expense (reversal) changed year-over-year?
ClearPoint Neuro's accounts receivable, credit loss expense (reversal) decreased by 143.8% year-over-year, from $217K to -$95K.